It’s been a quick-paced week in the world of startups and tech innovation, with news flying in from all corners…
Read More
Swiss BioTech platform NUCLIDIUM raises €84 million for the diagnosis and treatment of cancer
Basel-based NUCLIDIUM, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced the successful closing of its Series…
Read More
Nuclidium Nets $99M Series B for Copper-Based Radiopharma Platform
Nuclidium’s coin purse is approximately $99 million heavier after the Swiss biotech closed its series B round on Thursday. Unlike…
Read More
